Compare CVS Health Corp (CVS) vs MPLX LP (MPLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs MPLX LP — how do they compare? CVS Health Corp trades at $85.76 (market cap $112.29B), while MPLX LP trades at $57.6 (market cap $58.11B). The key difference: CVS Health Corp is the larger of the two by market cap, and MPLX LP pays the higher dividend (7.51%). Which is the better fit depends on your goals.
| CVS | MPLX | |
|---|---|---|
Market Cap | $112.29B | $58.11B |
Volume | 7,763,676 | 687,483 |
Sector | Health | Energy |
52-Week High | $110.60 | $60.51 |
52-Week Low | $70.08 | $47.80 |
Typical Hold Time | 83 Days | — |
Enterprise Value | $174.64B | $83.22B |
Dividend Yield | 3.03% | 7.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.95, up 1.76% on the day, with a bullish technical signal and strong analyst support. Recent earnings beats in Q1 and Q2 2026, alongside steady revenue growth to $402.07B in 2025, highlight operational strength. The stock's valuation appears attractive with a P/E of 23.17 and P/S of 0.27, while a consensus price target of $111.20 suggests significant upside potential. Positive news includes Aetna's 2027 Medicare plan enhancements and a declared quarterly dividend.
The outlook for CVS remains positive, driven by earnings momentum and strategic initiatives in healthcare services. Key risks include reimbursement pressures and regulatory scrutiny, but Wall Street's 85% buy rating and institutional interest underscore confidence. Investors should weigh the stock's growth prospects against margin volatility and debt levels, with the current price offering a favorable entry point relative to targets.
MPLX trades at $57.05, down 1.25% with a bearish technical signal. The company maintains strong fundamentals with $11.47B revenue and 40.45% net margin, though recent earnings missed expectations in Q1 and Q2 2026. Analyst consensus remains bullish with a $63.80 price target, supported by stable cash flow and a resilient midstream business model that limits commodity price exposure.
The outlook is cautiously optimistic given MPLX's fee-based revenue structure and 67.86% buy rating from analysts. Key risks include energy market volatility and potential diesel export restrictions, but the company's distribution coverage ratio of 1.3x supports dividend sustainability. Upside potential exists if Q3 earnings meet or exceed the $1.15 EPS estimate due November 3, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →
